Overview

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and efficacy of TRx0237 in the treatment of subjects with mild Alzheimer's Disease.
Phase:
Phase 3
Details
Lead Sponsor:
TauRx Therapeutics Ltd